Ozempic Label Update: Warning of Intestinal Blockage Risk
September 27, 2023 – Ozempic and the Risk of Intestinal Blockage
On September 27, 2023, a significant update was announced for Ozempic, a medication primarily used for type 2 diabetes and off-label for weight loss. The drug’s labeling is now revised to include warnings about the risk of intestinal blockage. This update lends support to ongoing lawsuit claims related to the drug.
Our Firm’s Role in Uncovering the Risk
Our legal team played a pivotal role in bringing this issue to light. By obtaining internal FDA documents through the Freedom of Information Act (FOIA), we exposed the risks associated with Ozempic. These documents were made publicly available in June 2023.
Key Documents Revealed
Here are direct links to the documents provided to our firm by the FDA through our FOIA requests:
- FDA Email to GLP-1 Makers Confirming Risk
- FDA Correspondence to GLP-1 Makers Requiring Label Change
- FDA Pharmacovigilance Review of GLP-1 Drugs Dated November 2022 Confirming Risk
Associated Risks and Injuries
Studies link these drugs not only to intestinal blockage but also to serious conditions like gallbladder disease.
Seeking Legal Advice?
If you or a loved one have experienced serious adverse events such as intestinal obstruction or acute gallbladder disease from drugs like Ozempic, Rybelsus, Victoza, Tulicity, and Mounjaro, the Levensten Law Firm is here to assist. Contact us at 215-545-5600 to understand your rights and explore options for compensation claims.
